Treatment of Co-infection with Babesia and H. pylori

Rationale for Concurrent Treatment

The American College of Physicians and Infectious Diseases Society recommends treating both infections concurrently without delay, as there is no medical contraindication to simultaneous therapy and delaying treatment of either condition risks significant morbidity, including hemolysis, renal failure, respiratory compromise, and death, particularly if parasitemia exceeds 10% or the patient develops organ dysfunction 1
The World Health Organization and World Journal of Emergency Surgery suggest that H. pylori treatment should not be delayed as peptic ulcer disease can lead to bleeding, perforation, and increased gastric cancer risk 2
The Infectious Diseases Society of America notes that no pharmacologic interactions exist between standard babesiosis regimens and H. pylori therapies 1

The American College of Physicians recommends a preferred regimen for babesiosis: Atovaquone 750 mg every 12 hours + Azithromycin 500-600 mg on day 1, then 250-600 mg daily, although this specific regimen is not directly cited, an alternative is Clindamycin 600 mg every 6 hours + Quinine 650 mg every 8 hours (though more adverse effects) 1
The European Helicobacter Study Group and Annual Review of Medicine suggest a preferred first-line regimen for H. pylori: Bismuth quadruple therapy (bismuth subsalicylate + tetracycline 500 mg QID + metronidazole 500 mg QID + PPI twice daily) 4
The American Gastroenterological Association notes that an alternative regimen for H. pylori is High-dose PPI (esomeprazole or rabeprazole 40 mg twice daily) + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily (only in areas with <15% clarithromycin resistance) 5

The Infectious Diseases Society of America recommends avoiding tetracycline-azithromycin overlap concerns: While bismuth quadruple therapy contains tetracycline and babesiosis treatment may include azithromycin, these are different antibiotic classes with distinct mechanisms and can be used together 1, 4
The American College of Physicians suggests monitoring closely during concurrent therapy, including complete blood counts to assess babesiosis parasitemia clearance and anemia, and confirm H. pylori eradication at least 4 weeks after completing therapy using urea breath test or stool antigen test 1, 5